Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02970162 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
A Phase 3 study of Lambert-eaton Myasthenic Syndrome, sponsored by Catalyst Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02970162 is a Phase 3 study of Lambert-eaton Myasthenic Syndrome that has completed, run by Catalyst Pharmaceuticals. The registered enrollment target is 26 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02970162, a Phase 3 study of Lambert-eaton Myasthenic Syndrome, has completed, sponsored by Catalyst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during this double-blind study.
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Amifampridine Phosphate
Study Locations (1)
California
- UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02970162
The ClinicalTrials.gov registry entry for NCT02970162 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catalyst Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lambert-eaton Myasthenic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT02970162 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02970162 about?
NCT02970162 is a clinical study titled "Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)". This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during this double-blind study.
What is the current status of trial NCT02970162?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2016-11. Estimated completion is 2017-10.
What conditions does trial NCT02970162 study?
This clinical trial studies the following conditions: Lambert-eaton Myasthenic Syndrome.
What interventions are being tested in trial NCT02970162?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Amifampridine Phosphate (DRUG).
Who is sponsoring clinical trial NCT02970162?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02970162 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lambert-eaton Myasthenic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.